Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Sinotherapeutics Inc., a China-based specialty pharmaceutical company, to be the exclusive U.S. distributor of Posaconazole Delayed-Release Tablets 100mg. Sinotherapeutics has received final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Posaconazole Delayed-Release Tablets 100mg, which is an AB-rated generic equivalent of Merck’s Noxafil® Delayed-Release Tablets. Lannett expects to commence shipping the product shortly.
The brand product’s annual U.S. sales were approximately $325 million for the twelve months ended June 2019, according to IQVIA, although actual generic market values are expected to be lower.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.